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ABSTRACT OF DISSERTATION 
 
Nuclear export factor 3 regulates the localization of small nucleolar RNAs 
 
By 
 
Melissa Wanling Li 
 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2017 
 
Professor Jean E. Schaffer, Chairperson 
 
Metabolic diseases, such as obesity and diabetes, are associated with excess levels of 
lipids, which can lead to organelle dysfunction, cell death and eventually organ 
dysfunction. This process, termed lipotoxicity, is still not completely understood. In a 
genetic screen used to identify genes critical for lipotoxicity, the Schaffer lab has 
identified small nucleolar RNAs (snoRNAs) within the ribosomal protein L13a (Rpl13a) 
locus that mediate the cellular response to lipotoxic and general metabolic stress. 
These snoRNAs are non-canonical in that they accumulate in the cytosol after 
metabolic stresses like lipotoxicity and oxidative stress, suggesting that cells have 
specific mechanisms for regulating snoRNA distribution within the cell. 
 
To begin elucidating the underlying mechanism of snoRNA transport from the nucleus 
to the cytoplasm during metabolic stress, we modeled oxidative stress by treating cells 
with the chemotherapeutic drug doxorubicin (DOX). DOX is a potent inducer of 
superoxide through the activation of NADPH oxidase splice isoform 4D (NOX4D) and 
results in the cytosolic accumulation of Rpl13a snoRNAs. NOX inhibitors and genetic 
	 xi	
knockdown of NOX4D led to a decrease in the accumulation of Rpl13a snoRNAs in the 
cytosol after DOX treatment. Furthermore, RNA-sequencing studies demonstrated that 
snoRNAs as a class accumulated in the cytosol after DOX treatment, while 
simultaneous treatment with NOX inhibitors blunted the increase in cytosolic levels of 
snoRNAs. Together, these data indicate that snoRNAs as a class are present in the 
cytoplasm, where their levels are dynamically regulated by NOX4D during oxidative 
stress.  
 
The finding that loss-of-function of NXF3, a member of the nuclear export family of RNA 
transporters, protects cells from lipotoxic cell death suggested that this protein may 
function as a regulator of snoRNA distribution. In transient transfection assays, NXF3 
knockdown increased abundance of cytosolic Rpl13a snoRNAs, whereas NXF3 
overexpression led to decreased cytosolic levels. These observations suggested that 
snoRNAs traffic constitutively between the nucleus and cytoplasm, and NXF3 functions 
to efficiently concentrate snoRNAs in the nucleus. Consistent with a role for NXF3 as a 
snoRNA transporter, we found the Rpl13a snoRNAs co-immunoprecipitated with NXF3. 
Treatment of cells with forskolin caused a rapid decrease in cytosolic snoRNAs and 
increased both nuclear localization of NXF3 and association of NXF3 with Rpl13a 
snoRNAs. These effects of forskolin were abrogated by NXF3 knockdown.  
 
Our findings identify a novel trafficking pathway for snoRNAs that cycle between the 
nucleus and the cytosol. This pathway is regulated by oxidative stress and levels of the 
RNA transporter NXF3.  
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CHAPTER ONE:  
Introduction 
 
1.1 Obesity and diabetes are global health concerns 
Obesity is a major risk factor for metabolic diseases such as diabetes, and both have 
become increasingly prevalent worldwide. Obesity has more than doubled since 1980. 
In 2014, more than 1.9 billion adults were overweight, 600 million of whom were obese 
and 422 million of whom were diagnosed with diabetes (WHO Diabetes fact sheet, 
2016). These diseases have been attributed to accelerated urbanization, increased 
caloric intake, changes in types of caloric intake, and sedentary lifestyles (WHO 
Diabetes fact sheet, 2016; Globalization of Diabetes Hu, 2011). 
 
Many complications can arise from obesity and diabetes, and these contribute to 
substantial morbidity and mortality. Cardiovascular disease accounts for 51% of deaths 
in patients with type 1 diabetes and 52% of deaths in patients with type 2 diabetes 1. 
Diabetic heart diseases include coronary heart disease (CHD) and heart failure. CHD 
occurs when atherosclerotic plaque builds up inside coronary arteries, a condition that 
causes myocardial infarction. Although heart failure can result from the damage caused 
by infarcts, a clinically distinct form of heart failure called diabetic cardiomyopathy 
(DCM) is characterized by ventricular dilation, myocyte hypertrophy, interstitial fibrosis 
and decreased diastolic and/or systolic function that occurs in the absence of underlying 
atherosclerotic disease 2-4.  
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In addition to macrovascular complications, diabetic individuals have an increased 
prevalence in microvascular complications, such as diabetic retinopathy, which is the 
leading cause of blindness (NEI Diabetic Retinopathy, 2010), and diabetic neuropathy, 
which accounts for 60% of non-traumatic lower-limb amputations in American adults 
(CDC National Diabetes Statistics Report, 2014). Diabetes is also the primary cause of 
kidney failure accounting for 44% of new cases (CDC National Diabetes Statistics 
Report, 2014). In addition to vascular diseases, people with diabetes are also at a 
higher risk for some cancers 5. 
 
Currently, obesity and diabetes are linked to more deaths worldwide than malnutrition 
(WHO Diabetes fact sheet, 2016). In 2016, 1.5 million deaths were directly caused by 
diabetes, which is the seventh leading cause of death overall (CDC At a Glance Fact 
Sheets 2016). Given the high prevalence of obesity and diabetes, the medical costs of 
treating the disease and its associated complications have become enormous. It is 
estimated that the cost of diabetes care in 2015 alone worldwide was $1.31 trillion USD 
6. A greater understanding the pathogenesis of this disease is essential to decrease 
morbidity and mortality and to reduce this growing socioeconomic burden worldwide.  
 
1.2 Systemic metabolic abnormalities in diabetes 
As the primary source of the body’s energy, blood glucose levels are tightly regulated to 
keep the body in homeostasis. When blood glucose levels are low, pancreatic α-cells 
secrete glucagon that converts glycogen into glucose in order to raise blood glucose 
levels. Meanwhile, when glucose levels are high, pancreatic β-cells release insulin, 
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which signals to cells to take up glucose from blood through the GLUT4 transporter and 
to liver and muscle cells to store glucose as glycogen, both of which lower blood 
glucose levels. Inadequate insulin action and hyperglycemia is a hallmark of diabetes. 
In type 1 diabetes patients, the immune system destroys β-cells, preventing the 
pancreas from producing insulin. It is thought to arise from genetic factors and 
environmental triggers. However, type 1 diabetes accounts for only 5-10% of all 
diabetes cases 7. By contrast, in type 2 diabetes, the pancreas produces insulin, but 
tissues in the body become resistant to the actions of the hormone. The inability of 
insulin to signal to tissues to take up blood glucose leads to hyperglycemia 8.  With 
obesity on the rise, type 2 diabetes cases have also increased, with the number of 
Americans diagnosed with diabetes increasing fourfold from 1980 through 2014 (5.5 
million to 22.0 million) (CDC Diagnosed Diabetes, 2015). Prolonged exposure of 
hyperglycemia has been linked to the pathogenesis of complications in both type 1 and 
type 2 diabetes, including heart disease, retinopathy and glomerulopathy 9-11.  
 
Large multicenter studies that have tested the ability of tight glycemic control for the 
prevention of complications have provided evidence for efficacy in preventing some, but 
not all diabetic complications. For example, the DCCT/EDIC trial demonstrated that tight 
glycemic control in patients with type 1 diabetes reduced the incidence and severity of 
macrovascular and microvascular disease 12. However, in the ACCORD trial, treating 
hyperglycemia alone in type 2 diabetes was sufficient to decrease microvascular 
complications, but did not have a beneficial effect on macrovascular complications such 
as CHD 13. These findings and similar observations in other studies of type 2 diabetes 
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suggested that other associated metabolic disturbances in diabetes may contribute 
importantly to complications. For example, in addition to hyperglycemia, patients with 
type 2 diabetes often have high circulating triglycerides and free fatty acids (FFA) 14-16. 
Hypertriglyceridemia is linked to the incidence and severity of complications, including 
neuropathy, retinopathy, non-alcoholic steatohepatitis, heart failure 17-20.  
 
1.3 Lipotoxicity 
FFAs and their metabolites are crucial as an energy source, as components of cellular 
membranes, and as signaling molecules in many physiological processes. Besides 
exogenous sources of FFA in the diet, lipogenic tissues can generate lipids de novo 
from excess carbohydrates 21. In conditions of nutritional excess, FFAs are metabolized 
to triacylglycerides (TAGs) and stored in neutral lipid droplets in adipose depots. During 
nutritional deprivation or sympathetic stimulation, TAGs are hydrolyzed into glycerol and 
FFAs, which are released into the bloodstream for distribution of this energy source to 
peripheral tissues. The liver also produces FFA and triglycerides, which are secreted 
into the circulation as lipoproteins. The hormone insulin negatively regulates lipolysis in 
adipose tissue and de novo lipogenesis in the liver. In the setting of insulin resistance, 
levels of lipids in the blood stream are high and can further contribute to insulin 
resistance in tissues such as skeletal muscle 22-24. Hyperlipidemia may also reflect the 
finite capacity for expansion of adipose tissue stores of triglyceride in obesity.  
 
Hyperlipidemia causes increased delivery of FFA and triglycerides to non-adipose 
tissues. These tissues have some capacity to metabolize or store FFA as triglyceride in 
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ectopic lipid droplets. Studies of cultured cells and animal models suggest that this initial 
storage of excess lipid as triglyceride is protective 25-28. However, this capacity for 
triglyceride storage in non-adipose tissues is limited. Ultimately, FFA that fail to be 
sequestered in triglyceride droplets or that are released from TAG hydrolysis can lead to 
cell dysfunction and eventually cell death, a process termed lipotoxicity.  
 
Hyperlipidemia also induces generation of reactive oxygen species (ROS). ROS are 
highly reactive molecules with an unpaired electron that are produced during normal 
cellular metabolism. One source of endogenous ROS is the electron transport chain 
(ETC) in the mitochondria. As electrons are shuttled through the ETC, incomplete one-
electron reduction of oxygen can occur, generating superoxide (O2-), instead of 
reduction of oxygen to water. In addition, there are several enzymatic pathways that 
produce ROS 29. For example, nicotinamide adenine dinucleotide phosphate oxidase 
(NOX) is an oligomeric protein that can generate O2- 30. Besides the NOX family, other 
enzymes that produce ROS include myeloperoxidase, which is expressed in neutrophils 
and produces hypochlorous acid; xanthine-oxidase, which catalyzes the oxidation of 
xanthine or hypoxanthine into uric acid; and nitric oxide synthase, which synthesizes 
nitric oxide required for vascular tone, neurotransmission and inflammation 29. Cells 
express several ROS scavenging enzymes, such as catalase and glutathione 
peroxidases, and proteins with redox active centers that protect against oxidative stress 
and enable cells to maintain ROS levels at relatively low levels during homeostatic 
conditions. Nonetheless, certain stresses, such as hyperlipidemia, trigger an increase in 
ROS production that exceeds the cell’s antioxidant capacity. When this occurs, high 
	 6 
levels of ROS can damage DNA, post-translationally modify proteins in ways that alter 
their function, and lead to lipid peroxidation 29. For example, excess free fatty acids, 
present in metabolic diseases such as type 2 diabetes, produce high levels of ROS 
through activation of NOX, through membrane remodeling, and through prolonged ER 
stress that ultimately lead to cell dysfunction and cell death 31-34.  
 
The proper function of the endoplasmic reticulum (ER) is necessary for lipid and protein 
metabolism under homeostatic conditions. Mutant proteins disrupt protein folding in the 
ER, leading to a halt in protein translation, degradation of misfolded proteins, and 
activation of signal pathways that increase the production of chaperones involved in 
protein folding. If the ER stress is not resolved, this triggers the activation of pro-
apoptotic genes and activation of NOX resulting in oxidative stress  35,36. Lipids also 
cause ER stress. As the major site for synthesis of lipids that constitute biological 
membranes, the ER plays an important role in membrane lipid homeostasis. Treating 
cells with pathophysiological levels of saturated fatty acid palmitate, but not general 
oxidative stress-inducer H2O2, leads to a change in ER membrane composition, thus 
compromising ER structure and integrity 31. The resulting ER and oxidative stress lead 
to cellular dysfunction and ultimately, cell death 31,37. However similar concentrations of 
unsaturated long-chain FFAs are well tolerated. Studies have shown that co-treating 
cells with saturated and unsaturated long-chain FFAs rescues cells from lipotoxicity 
31,38. These observations have been linked to the greater capacity of cells to store 
unsaturated FFA as triglyceride and the ability of of unsaturated FFA to enhance 
palmitate incorporation into triglyceride stores 26. 
	 7 
 
On a systemic level, prolonged hyperlipidemia has been associated with dysfunction of 
many organs. In diabetes, non-alcoholic steatohepatitis 39, glomerulopathy 40, and 
cardiomyopathy 41 are associated with ectopic lipid accumulation in these non-adipose 
tissues. In patients with congenital lipodystrophies, diminished or absent adipose tissue 
leads to ineffective FFA storage and hyperlipidemia that is associated with profound 
non-alcoholic steatohepatitis and systemic insulin resistance 42. Although strategies to 
decrease serum lipid levels through behaviorial interventions, such as exercise and 
improved diets, or by inhibiting de novo lipogenesis can be efficacious, strategies to 
prevent lipotoxicity are limited by our incomplete knowledge of the mechanisms 
underlying FFA-induced cellular injury.  
 
1.4 Rpl13a snoRNAs mediate cellular response to metabolic 
and oxidative stresses 
In order to identify novel regulators of the cellular response to lipid overload, the 
Schaffer lab has used a cell culture model of lipotoxicity in which non-adipose cells are 
grown in media supplemented with pathophysiological levels of the saturated fatty acid 
palmitate. Under these conditions, fibroblasts, hepatocytes, cardiomyoblasts, and 
endothelial cells develop ER and oxidative stress and ultimately die over the course of 
24 to 48 hours.  The Schaffer lab used this model to perform a loss-of-function genetic 
screen using the ROSABgeo promoter trap.  The integrated ROSABgeo provirus 
contains B-galactosidase-neomycin phosphotransferase fusion cassette with a strong 
polyadenylation sequences, but lacks its own promoter. Therefore, the ROSABgeo 
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transcript is only expressed if it integrates downstream of an actively transcribed RNA 
polymerase II promoter. In this case, the neomycin phosphotransferase activity allows 
the mutant to survive neomycin selection, and because of the strong polyadenylation 
sequence, the endogenous gene at the site of the integration is no longer expressed. 
The genetic screen was performed in Chinese hamster ovary (CHO) cells, and mutants 
with single promoter trap integrations were selected for growth over 48 hours in the 
presence of lipotoxic levels of palmitate 31,43-46. 
 
The locus encoding ribosomal protein L13a (Rpl13a) was identified as the site of 
mutation in one of these mutant cell lines and is necessary for the production of 
oxidative stress and cell death in response to lipotoxic stress 45.  The eight exons in this 
locus encode the Rpl13a protein, a constituent of the large ribosomal subunit. This 
locus also contains four intronic box C/D small nucleolar RNAs (snoRNAs)—U32a, U33, 
U34, and U35a—that are produced from the intron lariats generated during splicing of 
the Rpl13a pre-mRNA. Through complementation and directed knockdown 
experiments, the Schaffer lab showed that loss of the intronic Rpl13a snoRNAs, rather 
than the Rpl13a protein, were responsible for palmitate resistance in the mutant cell 
line. Furthermore, while the Rpl13a snoRNAs are enriched in the nucleus of wild type 
cells under basal conditions, they are also detected in the cytoplasm and they rapidly 
accumulate in the cytosol in response to lipotoxicity and general inducers of oxidative 
stress 44,45,47. Another mutant isolated from the screen had a disruption in the SmD 
locus, a core component of the spliceosome that was shown to be necessary for the 
correct processing of snoRNAs from intron lariats 46. Intriguingly, haploinsufficiency of 
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the Rpl13a snoRNAs is sufficient to confer protection from lipotoxicity, but does not alter 
the 2’-O-methylation of predicted rRNA targets 45. Together, these experiments suggest 
a potential non-canonical role for the Rpl13a snoRNAs outside of the nucleus in the 
cellular response to metabolic stress.  
 
1.5 Small nucleolar RNAs 
The Rpl13a snoRNAs are members of a broader class of short noncoding RNAs that 
range from 60-200 nucleotides long. Most mammalian snoRNAs, including the Rpl13a 
snoRNAs, are encoded within introns, are processed out of intron lariats during splicing, 
and lack a 5’ cap structure. There is a small subset of snoRNAs that are independently 
transcribed by RNA polymerase II that includes U3, U8 and U13, and in their mature 
form contain an m3G cap 48. SnoRNAs are categorized as belonging to the box C/D or 
box H/ACA class based on conserved sequence motifs. Both classes of snoRNAs 
complete their maturation to functional ribonucleoproteins (RNPs) with a core set of 
proteins in Cajal bodies and then localize within the nucleolus.  
 
Most snoRNAs are known to function in the covalent modification of other noncoding 
RNAs within the nucleolus. Specifically, box C/D snoRNAs complex with the 
methyltransferase fibrillarin and guide 2’-O-methylation of ribosomal RNAs (rRNA), 
while box H/ACA snoRNAs complex with the pseudouridine synthase dyskerin and 
guide pseudouridylation of rRNAs. Both classes of snoRNAs contain short (10-20 
nucleotides for box C/D snoRNAs) antisense elements that are complementary to the 
sequence of their target RNAs, and serve as zipcodes to target the mature snoRNPs to 
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bind specific sites of modification on the target RNAs. SnoRNAs that stay and function 
within the Cajal bodies are called small Cajal body-specific RNA (scaRNA). ScaRNAs 
guide 2’-O-methylation and pseudouridylation on small nuclear RNAs (snRNA) 49. A 
number of snoRNAs are considered orphans on the basis that there is no known target 
rRNA 50. In some instances, snoRNA-directed modifications have been shown to be 
necessary for proper ribosome and spliceosome function 51-54, for processing of pre-
rRNA species 55, or for stability of rRNA 56. In addition, there is a growing body of 
evidence of snoRNA roles outside of rRNA or snRNA modification, including roles in 
modification of pre-mRNAs to direct splicing 57, regulation of RNA editing 58, miRNA-like 
post-transcriptional regulation 59, and pseudouridylation of mRNA targets 60.   
 
Recent studies also provide evidence for novel functions of snoRNAs in disease states. 
In a knock-in mouse model with loss-of-function of the Rpl13a snoRNAs generated by 
the Schaffer lab, cells and tissues from the knock-in mouse have lower basal ROS tone 
and are resistant to metabolic stress and diabetogenic stimuli 61. This suggests that 
Rpl13a snoRNAs could play a role in metabolic diseases. SnoRNAs have also been 
implicated in cancer. Box C/D snoRNA U50 is downregulated in prostate cancer and 
breast cancer 62, while box H/ACA snoRNA SNORA42 is overexpressed in non-small-
cell lung cancer 63. Furthermore, deletions that included loss of box C/D snoRNAs 
SNORD14D, SNORD43, U34 and U35a, suppressed leukaemogenesis 64. Together, 
these findings implicate snoRNAs in disease pathogenesis. 
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The finding that Rpl13a snoRNAs are present in the cytosol under homeostatic 
conditions and the observation that metabolic stress conditions regulate the cytosolic 
levels of these and other snoRNAs suggests these non-coding RNAs could have 
functions outside the nucleus. Since knockdown and loss-of function approaches to 
study the functions of snoRNAs affect the nuclear and cytosolic pools of the targeted 
species, these approaches have limited ability to identify roles of snoRNAs in specific 
subcellular compartments. In order to elucidate potential functions of snoRNAs in the 
cytosol, it would be ideal to disrupt trafficking of these non-coding RNAs out of the 
nucleus. However, mechanisms that regulate movement of snoRNAs between the 
nucleus and cytoplasm are poorly characterized. In the present study, we demonstrate 
that the dynamic localization of snoRNAs is regulated by superoxide through DOX-
induced activation of enzyme NOX4D. 
 
1.6 RNA transporters 
Most RNAs exit the nucleus complexed as RNPs through the nuclear pore complexes 
(NPC) that are made up of nucleoporin proteins. Members of the nuclear export factor 
(NXF) family play important roles in the export of RNA by physically interacting with the 
nucleoporins to facilitate export. The NXF family is comprised of five functional 
members NXF1, NXF2, NXF3, NXF5 and NXF7. NXF family members have been 
identified based on similarity of sequence and domain architecture. Most include an 
amino terminal RNA binding interaction domain, a p15/NXFt-heterodimerization domain 
that recruits NXF adaptor p15 necessary for nuclear transport, and a carboxyl terminal 
ubiquitin associated domain involved in NPC binding 65,66. 
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NXF family members have been shown to function in the transport of specific classes of 
RNAs. For example, Nuclear export factor 1 (NXF1) is considered the bulk mRNA 
transporter. NXF1 operates with several other proteins, including ALY and a cap-binding 
complex, which help target its mRNA cargo, and with p15, which helps the NXF1-mRNA 
complex physically interact with nucleoporins to exit the nucleus through the NPC. 
Unlike other RNA transport, NXF1-mediated mRNA export is RanGTP independent 
indicating that directionality of transport is established through a different mechanism 67. 
NXF2, NXF3 and NXF5 have also been shown to function in the nuclear export of 
mRNAs, whereas NXF7 has been proposed to function in the cytoplasmic trafficking of 
mRNAs 68-73.  
 
Other classes of transporters have been shown to be involved in nucleocytoplasmic 
transport of small RNA species. The transport of tRNAs is mediated through exportin-t 
and transport of miRNAs is mediated through exportin-5. Both exportins directly bind 
their target RNA in an RanGTP-dependent manner. The exportin-RNA-RanGTP 
complex is exported through the NPC to the cytoplasm where RanGTP is hydrolyzed, 
thus releasing its cargo in the cytoplasm.  Export receptor CRM1 is required for snRNA 
export and is also RanGTP-dependent. However, unlike tRNA and miRNA export, in 
which their specific export receptors bind directly to their target RNA, CRM1 requires 
adaptor protein PHAX and a cap binding complex to bind to its RNA cargo 67.  
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SnoRNAs have long been thought to complete their biogenesis and function within the 
nucleus. In eukaryotic cells, most snoRNAs are encoded within pre-mRNA introns, while 
some snoRNAs are independently transcribed. Both types of snoRNAs are transcribed 
in the nucleus. SnoRNP proteins, like fibrillarin and dyskerin, bind immature pre-
snoRNAs while they are trimmed by exonucleases in the nucleoplasm. The snoRNPs 
are then trafficked to the Cajal bodies for maturation. Mature snoRNPs either stay within 
the Cajal body, as is the case for scaRNAs, or traffic to the nucleolus where they guide 
the modification of newly synthesized rRNAs 51,54,74. Nuclear export receptors PHAX 
and CRM1 are necessary to sequentially transport independently-transcribed snoRNA 
U3 from the Cajal body to the nucleolus for correct snoRNP maturation 75. Although 
PHAX and CRM1 can also function as export receptors, there is not evidence that they 
are involved in nucleocytoplasmic transport of U3 or other snoRNAs.  
 
Nonetheless, several studies suggest that cells have endogenous mechanisms for 
transport of independently transcribed and capped snoRNAs between the nucleus and 
cytoplasm. Xenopus oocytes provide evidence for an endogenous pathway that 
transports capped U3 from the cytoplasm to the nucleus following microinjection of in 
vitro transcribed U3 75. Moreover, U8 snoRNA associates with the import factor 
snurportin 1 in mammalian cells, and knockdown of this transport adaptor is associated 
with increased cytosolic U8 76. Whether snurportin 1 serves a broader role in transport 
of the overall class of snoRNAs, and whether other transport proteins function to 
regulate the distribution of snoRNAs between the nucleus and cytoplasm is not known. 
In particular, it is uncertain whether these mechanisms apply to intronic, uncapped 
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snoRNA transport. In the present study, we identified nuclear export factor (NXF3) as a 
snoRNA nucleocytoplasmic transporter that can be regulated by cyclic AMP and ROS 
levels.  
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CHAPTER TWO: 
Metabolic stress regulates snoRNA trafficking 
 
2.1 INTRODUCTION 
The four intronic box C/D snoRNAs from the Rpl13a locus are critical mediators of 
lipotoxicity 45. Although snoRNAs are thought to reside and function exclusively in the 
nucleolus, the Rpl13a snoRNAs rapidly accumulate in the cytosol when cells are 
exposed to pathophysiological levels of palmitate, a known inducer of oxidative stress. 
In addition, oxidative stress resulting from hydrogen peroxide treatment also causes 
these snoRNAs to accumulate in the cytosol 44,45. These observations suggested that 
ROS is an important regulator of snoRNA localization.  
 
Reactive oxygen species (ROS) are highly reactive molecules with unpaired electrons 
that are produced during normal cellular metabolism. A major source of endogenous 
ROS is the electron transport chain in the mitochondria 77. In addition, there are several 
enzymatic pathways that produce ROS 78. Nicotinamide adenine dinucleotide 
phosphate oxidase (NOX) is an oligomeric protein that can generate superoxide. There 
are seven isoforms of the NOX catalytic subunit, each characterized by a cytoplasmic 
N-terminus, six transmembrane domains, and a long cytosolic C-terminal tail. All seven 
isoforms, except for NOX5, require the transmembrane protein p22phox for stability and 
activation 30,79. However, the isoforms differ with respect to tissue distribution and 
subcellular localization. NOX2 is considered the prototype NOX. It is localized in the 
membranes of phagosomes and highly expressed in phagocyte-specific tissues, where 
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its ROS production contributes to the elimination of microbes 30.  On the other hand, 
NOX4 is known to localize in the mitochondria in the heart, where it is constitutively 
active 30,80. There are four splice variants of NOX4 (NOX4B, NOX4C, NOX4D and 
NOX4E) that may have different functions in ROS-related signaling. Specifically, splice 
variant NOX4D lacks the transmembrane domain and is found to localize within the 
nucleus 81,82, raising the possibility that it could be involved in generating ROS in the 
vicinity of snoRNAs.  
 
Although snoRNAs have been established as guides to 2’-O-methylation and 
pseudouridylation of other small noncoding RNAs within the nucleus, their role in the 
cytosol and regulation of their localization outside of the nucleus have previously not 
been investigated.  Our goal was to investigate the mechanisms underlying the cytosolic 
localization of Rpl13a snoRNAs under metabolic stress conditions and to determine 
whether the cytosolic localization applies specifically to the Rpl13a snoRNAs or to the 
snoRNAs as a class.    
 
2.2 RESULTS 
2.2.1 Doxorubicin treatment increases cytosolic Rpl13a snoRNA levels in 
cardiomyoblasts  
Our lab has previously demonstrated that the accumulation of cytosolic Rpl13a 
snoRNAs begin to accumulate in the cytosol after treatment with 6-8 h of palmitate or 3-
5 h of hydrogen peroxide, both of which induce high levels of cellular ROS 44,45. Another 
potent inducer of ROS is the chemotherapy drug doxouribicin (DOX) 83,84. We treated 
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H9c2 rat cardiomyoblasts with 20 µM DOX for 1 h, isolated the cytosolic and nuclear 
fraction of cells using sequential detergent extraction, and used RT-qPCR to measure 
levels of the Rpl13a snoRNAs relative to Rplp0. As expected, prior to DOX treatment, 
U32a, U33 and U34 levels were 400-500X more abundant in the nuclear fraction than 
the cytosolic fraction (Figure 2.1A). Cytosolic proteins (HSP90, α-tubulin) were enriched 
in the cytosolic fraction while nuclear proteins (nucleophosmin and histone H3) were 
enriched in the nuclear fraction (Figure 2.1B). After DOX treatment, we detected 12-, 4-
, and 8-fold increases in the cytosolic abundance of U32a, U33, and U34 (Figure 2.1A). 
The levels of total and nuclear Rpl13a snoRNAs were not significantly increased after 
DOX treatment and the nuclear proteins did not appear in the cytosolic fraction after 
DOX treatment. This suggests that the observed increase in the Rpl13a snoRNAs is not 
due to any decrease in nuclear integrity or overall increase in total snoRNA levels 
(Figure 2.1A-C).  
 
2.2.2 Superoxide is necessary for cytosolic Rpl13a snoRNA accumulation during 
doxorubicin treatment 
DOX has been shown to induce superoxide through the NOX enzymes 85,86. To 
determine whether the localization of the Rpl13a snoRNAs during DOX treatment was 
dependent on superoxide, we tested whether NOX inhibitor DPI or the superoxide 
scavenger Mn(III)TMPyP (MnT) could inhibit the cytosolic accumulation of the Rpl13a 
snoRNAs. Co-treatment of H9c2 rat cardiomyoblasts with DPI or MnT, blunted the 
DOX-induced accumulation of cytosolic Rpl13a snoRNAs (Figure 2.2A). Moreover, 
treating H9c2 rat cardiomyoblasts with DPI alone resulted in lower levels of cytosolic 
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snoRNAs (Figure 2.2B). Together, these results suggest the production of superoxide 
by a NOX enzyme is required for Rpl13a snoRNA accumulation in the cytosol both after 
DOX treatment and under normal homeostatic conditions. We next tested whether the 
inhibitory effects of DPI and MnT on cytosolic snoRNA accumulation simply reflected 
inhibition of DOX-induced nucleolar stress.  We performed immunofluorescence 
staining of the nucleolar protein nucleophosmin (NPM) to assess nucelolar integrity 
during DPI, MnT and DOX treatments 87. Nucleolar punctae, present under basal 
conditions, were lost after DOX treatment, consistent with nucleolar stress, but NPM 
staining remained localized within the nucleus (Figure 2.2C). Thus, although MnT and 
DPI blunted the accumulation of cytosolic Rpl13a snoRNAs after DOX treatment, the 
drugs had no effect on the DOX-induced nucleolar stress, suggesting that the nucleolar 
dissolution is not dependent on superoxide or NOX activity. Together, our results are 
consistent with a model in which Rpl13a snoRNA accumulation in the cytosol is 
dependent on ROS and is not the result of generalized nucleolar stress. 
 
2.2.3 NADPH oxidase 4D mediates cytosolic Rpl13a snoRNA accumulation in 
response to doxorubicin treatment 
The ability of DPI and MnT to inhibit cytosolic snoRNA accumulation after DOX 
suggested a mechanism involving the NOX enzyme family. In cardiomyoblasts, NOX4 
activity is dependent on the p22 subunit, and one of its four splice variants, NOX4D, 
localizes in the nucleus and nucleolus 82,88. Given its localization, we hypothesized that 
NOX4D could generate nuclear ROS to impact snoRNA localization. Given the gene 
structure of NOX4D, it was not possible to design an siRNA specific to NOX4D (Figure 
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2.3). We used two independent siRNAs against the following targets: NOX4A at exons 3 
or 5 (siRNA NOX4A), both NOX4A and NOX4D isoforms at exons 12-13 or 14 (siRNA 
NOX4AD), or the regulatory p22 subunit. Following transfection of cardiomyoblasts, 
total mRNA levels of p22 were significantly knocked down by two independent siRNAs 
(Figure 2.4A). Total mRNA levels of NOX4A were significantly knocked down by all 
NOX4A and NOX4AD siRNAs (Figure 2.4B). Total mRNA levels of NOX4D were 
significantly knocked down only by NOX4AD siRNAs (Figure 2.4C). Knockdown of 
these targets was not affected by DOX treatment (Figures 2.4A-C). SiRNA against 
NOX4AD and p22 recapitulated the effects of MnT and DPI, significantly blunting 
cytosolic accumulation of Rpl13a snoRNAs after DOX treatment, whereas siRNA 
against NOX4A only had no significant effect (Figures 2.4D). These data implicate 
NOX4D as a mediator of cytosolic snoRNA accumulation in response to DOX treatment. 
Similar to DPI and MnT treatment, none of the siRNA knockdowns inhibited nucleolar 
stress induced by DOX (Figure 2.4E).  
 
2.2.4 SnoRNAs are dynamically regulated in the cytoplasm 
To determine whether ROS-regulated accumulation of snoRNAs in the cytosol is 
specific for Rpl13a snoRNAs or relevant to snoRNAs as a class of noncoding RNAs, we 
used RNA sequencing to analyze H9c2 rat cardiomyoblasts following treatment with 
DOX with or without DPI. We prepared small RNA-sequencing libraries from cytosolic 
RNA of 35-350 nucleotides in order to capture snoRNAs while minimizing overlap with 
miRNAs. For each condition, we generated 3 independent libraries that were 
sequenced on an Illumina HiSeq 2500. Aligned reads were annotated using Ensembl 
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Rat Build 369, which specifies 560 noncoding RNAs (ncRNA), including 215 
sno/scaRNAs. Total raw reads per condition were similar, as were the number of reads 
aligned to the genome and >99% of annotated reads corresponded to small ncRNA 
genes (Table 2.5A). DOX treatment resulted in a significant increase in both the 
number and proportion of annotated reads that mapped to box C/D snoRNAs (Table 
2.5A and Figure 2.5A). Significantly fewer box C/D snoRNAs were recovered with DPI 
treatment, similar to our findings for the Rpl13a snoRNAs. Cytoplasmic box H/ACA 
snoRNAs and scaRNAs followed the same pattern as box C/D snoRNAs, but did not 
reach statistical significance (Figure 2.5A).   
 
In our RNA-sequencing data, changes in the cytosolic abundance for U32a, U33 and 
U34 after DOX and/or DPI treatment were similar to those found by RT-qPCR (Figure 
2.5B, lower). The RNA-seq method was also able to detect a 3-fold increase in 
cytosolic U35a after DOX treatment, which was not detected by RT-qPCR. This may be 
due to the superior sensitivity of the RNA-seq method, as U35a is 100-fold less 
abundant than U34, the most abundant Rpl13a snoRNA (Figure 2.5B, upper).  
 
Overall, we detected 256 of 560 annotated small ncRNA, including 94 of the 119 
annotated box C/D snoRNAs, in the cytoplasm (Figure 2.5C). We determined 
differential representation in the cytoplasm after DOX treatment using normalized read 
counts and parameters of >2-fold change with false discover rate <0.05. The 105 genes 
that passed these criteria were all sno/scaRNA with increased cytosolic expression after 
DOX treatment, 89 of which were box C/D snoRNAs (Figure 2.5C). These significantly 
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increased box C/D snoRNAs account for 95% of the detectable cytoplasmic box C/D 
snoRNAs, suggesting a strong class effect. Although much fewer, annotated box H/ACA 
snoRNAs and scaRNA were detected in the cytosol, and more than half also showed 
significant increases in the cytosol after DOX treatment (Figure 2.5C). Together, this 
RNA-seq data provides evidence that DOX can induce the cytosolic accumulation of a 
broad range of snoRNAs through a NOX-dependent mechanism.  
 
2.3 CONCLUSIONS 
Through RT-qPCR and RNA-seq analyses, we have demonstrated that snoRNAs as a 
class are not exclusively localized to the nucleus. While the majority of the snoRNAs are 
localized within the nucleus under basal, homeostatic conditions, snoRNAs are 
detectable in the cytosol, where their cytosolic abundance is dynamically regulated by 
oxidative stress. Our results support a model in which DOX treatment induces NOX4D-
dependent nuclear superoxide, which leads to snoRNA accumulation in the cytosol 
(Figure 2.6).  
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2.4 FIGURES 
 
 
Figure 2.1 Doxorubicin treatment increases cytosolic Rpl13a snoRNA levels in 
cardiomyoblasts. H9c2 cardiomyoblasts were treated with vehicle alone (ctrl) or 20 µM 
DOX for 1 h. A-B. Cytosolic and nuclear extracts were prepared from ctrl and DOX 
treated cells by sequential detergent extraction. Cytosolic and nuclear RNA were 
quantified by RT-qPCR with normalization to the control transcript Rplp0. Error bars 
show 95% confidence interval for n = 3 independent experiments (A). Fractions were 
analyzed by western blot for cytosolic protein markers (HSP90, α-tubulin) and nuclear 
protein markers (NPM, histone H3) (B). C. Total RNA was assayed by RT-qPCR with 
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normalization to the control transcript Rplp0. Error bars show 95% confidence interval 
for n = 3 independent experiments.  
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Figure 2.2 Superoxide is necessary for cytosolic Rpl13a snoRNA accumulation 
during doxorubicin treatment. A. Cells were treated for 1 h with vehicle alone (ctrl) or 
combinations of 20 µM DOX, 500 nM DPI, and 200 µM MnT as shown. Cytosolic RNA 
was isolated by digitonin extraction and snoRNAs were analyzed by RT-qPCR relative 
to Rplp0. Error bars show 95% confidence interval for n = 3 independent experiments. 
B. Cells were treated with DPI or MnT alone. Cytosolic RNA was isolated by digitonin 
extraction and snoRNAs were analyzed by RT-qPCR relative Rplp0. Error bars show 
95% confidence interval for n = 3 independent experiments. C. Cells were analyzed by 
immunofluorescence microscopy for detection of NPM under ctrl and 1 h DOX-treated 
conditions and also in the presence of DPI or MnT. Micrographs show representative 
fields. Scale bar, 200 µM. *, p < 0.05 versus cyto/ctrl; &, p < 0.05 versus nuclear/ctrl; #, 
p < 0.05 versus DOX alone.  
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Figure 2.3 Exonic structure of NOX4A and alternatively spliced nuclear form 
NOX4D. Localization of siRNAs that target NOX4A only (exons 3 and 5) or both NOX4A 
and NOX4D (exons 12-13 and 14).  
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Figure 2.4 NADPH oxidase 4D mediates cytosolic accumulation of Rpl13a 
snoRNAs in response to doxorubicin treatment. A-D. H9c2 cardiomyoblasts were 
transfected for 24 h with siRNA targeting transcripts as shown: control (ctrl), p22, 
NOX4A, or NOX4AD. Cells were then treated with 20 µM DOX for 1 h where indicated. 
RNAs were quantified by RT-qPCR relative to Rplp0. Error bars show 95% confidence 
interval for n = 3 independent experiments. Total RNA was quantified for target 
knockdown with and without DOX treatment (A-C). Cytosolic snoRNAs were quantified 
after specified siRNA knockdown and DOX treatment (D). Cells were treated as above 
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and analyzed by immunofluorescence microscopy for localization of nucleolar marker 
NPM. Micrographs show representative fields (E). Scale bar, 200 µM. *, p < 0.05 versus 
ctrl; #, p < 0.05 versus ctrl/DOX; &, p < 0.05 versus NOX4A/DOX.  
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Figure 2.5 SnoRNAs are dynamically regulated in the cytoplasm. H9c2 
cardiomyoblasts were treated with 20 µM DOX in the absence or presence of 500nM 
DPI for 1 h. A. Normalized RNA-seq read counts for annotated cytosolic small ncRNA 
classes. Annotated reads were normalized as reads per million raw reads (RpM) and 
shown as the mean + standard error (SE) for n = 3 independent experiments . B. RNA-
seq expression data for the Rpl13a snoRNAs in response to treatment with DPI, DOX, 
or DPI/DOX. Read data are shown as RpM aligned reads to demonstrate the relative 
abundance of different Rpl13a snoRNA species (upper). These values were then further 
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normalized to the control sample and graphed to show relative expression by treatment 
(lower). Mean (+SE) for n = 3 independent experiments. C. The number of genes 
annotated for the rat genome (Ensembl ncRNA), number of genes detected 
experimentally in the cytoplasm by RNA-seq, and number of genes detected in the 
cytoplasm and up-regulated by DOX versus ctrl are shown by ncRNA subclass. *, p < 
0.05 for treatment versus ctrl; #, p < 0.05 for DPI/DOX versus DOX alone.  
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Table 2.5A Cytoplasmic RNA-seq reads (total per condition) 
  ctrl   DPI   dox   DPI/dox  
 Raw   15,777,864   14,321,914   16,038,254   16,539,780  
 Aligned   15,297,385   13,838,068   15,282,623   15,844,700  
 Annotated  11,026,233 9,976,388 11,264,042 11,475,445 
 Annotated ncRNA  10,972,911 9,931,129 11,201,347 11,418,071 
     
 sn/sno/scaRNA   453,102   285,808   2,472,756   1,709,804  
 miRNA   265,594   259,443   305,213   266,277  
 rRNA (5S + 5.8S)  10,243,718 9,376,317 8,413,350 9,431,538 
 misc   8,746   8,247   8,236   8,667  
     
 snRNA   5,275   4,959   6,105   4,469  
 scaRNA   1,828   1,221   13,340   8,989  
 C/D snoRNA   443,462   278,003   2,439,357   1,685,855  
 H/ACA snoRNA   2,537   1,625   13,954   10,491  
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Figure 2.6 Model for cytoplasmic snoRNA regulation. Doxorubicin (DOX) treatment 
induces high levels of superoxide through the activation of NOX4D enzyme and its 
regulatory subunit p22. The DOX-induced oxidative stress leads snoRNAs as a class to 
accumulate in the cytosol. NOX inhibitor DPI and superoxide scavenger MnT inhibit the 
ability of DOX to increase levels of superoxide and thus blunt the accumulation of 
snoRNAs in the cytoplasm.  
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CHAPTER THREE:  
NXF3 functions as a nucleocytoplasmic snoRNA 
transporter 
 
3.1 INTRODUCTION 
Following transcription, snoRNAs that are processed from the introns of pre-mRNA or 
that are generated from independently transcribed units, first move to Cajal bodies 
where they assemble in to mature snoRNPs, and subsequently to the nucleolus where 
they encounter nascent rRNA substrates. While Rpl13a snoRNAs localize primarily in 
the nucleus, these and other intronic snoRNAs are readily detected in the cytoplasm 
under homeostatic conditions 76,89, and they accumulate outside the nucleus during 
lipotoxic conditions, oxidative stress, and serum starvation 45,47,90. However, a 
nucleocytoplasmic trafficking pathway has not yet been identified for the class of 
snoRNAs. 
 
Nuclear export factor 3 (NXF3) was identified through an shRNA loss-of-function 
genetic screen in human umbilical endothelial cells (HUVECs) to identify genes required 
for the cytotoxic response to metabolic stress. Based on its sequence and functional 
domain similarities, NXF3 is considered to be a member of the nuclear export factor 
(NXF) family, which includes known mRNA exporter, nuclear export factor 1 (NXF1). 
However, NXF3 lacks the carboxyl terminal domain, ubiquitin-associated domain (UBA), 
which is involved in nuclear pore binding, and is required for nuclear export function of 
other family members 73. Nonetheless, previous studies have demonstrated that like 
other family members, NXF3 shuttles between the nucleus and cytoplasm.  A leucine 
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rich nuclear export sequence (NES) was identified within NXF3 that recruits CRM1, thus 
allowing NXF3 to export cargo through the nucleus 73, but no nuclear import sequence 
has been defined in the NXF3 sequence. In cells transfected with an HA-tagged form of 
NXF3 (HA-NXF3), Yang et al isolated poly(A) RNA/protein complexes using oligo dT 
cellulose. They demonstrated that there was a specific interaction between poly(A) RNA 
and HA-NXF3. This data implicated NXF3 in the nuclear export of mRNA. However, 
using oligo dT cellulose excludes noncoding RNAs, like snoRNAs, which are not 
polyadenylated. 73. The endogenous cargo for NXF3 remains to be defined, including 
determination of whether it can transport other RNA species like noncoding RNAs. 
Given that genetic screens implicated both Rpl13a snoRNAs NXF3 in lipotoxic response 
pathways, we hypothesized that NXF3 may also serve as a transporter for snoRNAs.  
 
3.2 RESULTS 
3.2.1 NXF3 knockdown protects against lipotoxic cell death in endothelial cells 
To identify genes critical for the cell death response to lipotoxicity, we performed a 
genome-wide loss-of-function shRNA screen in immortalized human umbilical vein 
endothelial cells (HUVECs), which are sensitive to lipotoxicity. Cells were transduced 
with pools of lentivirus containing shRNAs targeting expressed human genes and a 
puromycin selectable marker. HUVECs that survived puromycin selection were then 
treated for 48 hours in media supplemented with pathophysiological levels of palmitic 
acid to model lipotoxic conditions. Cells containing an shRNA targeting NXF3 had 
significantly improved survival compared to cells transduced with a non-targeting, 
control shRNA (Fig. 3.1A). The shRNA targeting NXF3 led to a 72% decrease in NXF3 
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mRNA levels (Fig. 3.1B) and a 28% decrease in NXF3 protein expression (Fig. 3.1C), 
consistent with knockdown of its gene target in these lipotoxicity-sensitive human cells. 
Together these observations implicate a critical role for NXF3 in the lipotoxic response 
pathway. 
 
3.2.2 NXF3 knockdown endothelial cells have aberrant Rpl13a snoRNA 
localization 
NXF3 is a member of the NXF family that includes the general mRNA export receptor, 
NXF1. While NXF3 can associate with mRNAs 91, other potential cargo such as 
noncoding RNAs have not been investigated. Given the important role of Rpl13a 
snoRNAs U32a, U22, U34, and U35a in lipotoxic and oxidative stress-induced cell 
death, and the observation that these snoRNAs accumulate in the cytoplasm under 
metabolic stress conditions 45,47, we hypothesized that NXF3 knockdown might affect 
localization of snoRNAs. We assessed Rpl13a snoRNA localization in cytosolic 
fractions of control- and NXF3-shRNA transduced cells by isolating cytosolic and non-
cytosolic fractions using digitonin extraction. Under normal homeostatic growth 
conditions, levels of cytosolic Rpl13a snoRNAs in NXF3 shRNA transduced cells were 
significantly increased compared with control shRNA transduced cells, while total levels 
of the snoRNAs did not significantly change (Figure 3.2A). Control western blots 
demonstrated that both nuclear (nucleophosmin) and cytosolic (HSP90, α-tubulin) 
markers segregated as expected in both control and NXF3 shRNA transduced cells 
(Figure 3.2B). Following treatment with hydrogen peroxide to induce oxidative stress, 
U32a, U33 and U34 snoRNAs accumulate in the cytoplasm of control shRNA 
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transduced HUVEC cells (Figure 3.2C), consistent with prior observations in other cell 
types that oxidative stress stimulates cytosolic accumulation of Rpl13a snoRNAs 44,47. In 
contrast, hydrogen peroxide did not cause further increase in the cytoplasmic levels of 
snoRNAs in NXF3 shRNA transduced cells. Hydrogen peroxide had no detectable 
effect on localization of U35a in shRNA transduced HUVEC cells, as has been 
observed for this less abundant Rpl13a snoRNA 47. Elevated cytoplasmic levels of the 
snoRNAs under homeostatic conditions in NXF3 shRNA-transduced cells is unlikely to 
be the result of increased basal oxidative stress or nucleolar stress, since intracellular 
ROS levels as assessed by dihydroethidium staining (Figure 3.2D) and nucleolar 
integrity as assessed by nucleophosmin staining (Figure 3.2E) were unchanged 
compared to control cells. Our findings that loss-of-function of NXF3 perturbs Rpl13a 
snoRNA subcellular localization indicates that NXF3 functions under homeostatic 
conditions to maintain the distribution of these non-coding RNAs between the nucleus 
and cytoplasm. Although NXF3 has been proposed as an mRNA export factor, 
accumulation of Rpl13a snoRNAs in the cytosol in the setting of NXF3 knockdown 
implicates an additional role for this protein in nuclear import of these small non-coding 
RNAs. 
 
3.2.3 Knockdown of NXF3 increases cytosolic Rpl13a snoRNAs in 
cardiomyoblasts 
We used transient knockdown to confirm our observations regarding NXF3 loss-of-
function in an independent cell type and compared the effects of knockdown of NXF3 
and related family member, NXF1 (Figure 3.3A). Compared to control non-targeting 
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siRNA, two independent siRNAs directed against NXF3 led to a 93% and 84% 
decrease, respectively, in NXF3 mRNA levels in H9c2 rat cardiomyoblasts, but did not 
significantly change levels of NXF1 (Figure 3.3B, left graph). Because we found that 
commercially available antibodies directed against rodent NXF3 are not specific for this 
family member (not shown), and our attempts to generate a specific antibody that 
recognizes the rat or murine protein were unsuccessful, extent of knockdown of the 
endogenous NXF3 protein could not be confirmed. Nonetheless, knockdown of NXF3 
mRNA by each siRNA led to a 50 to 200% increase in cytosolic levels of the Rpl13a 
snoRNAs (Figure 3.3B, right graph) without perturbing efficiency of fractionation 
(Figure 3.3C). In contrast, siRNA knockdown of NXF1 had no effect on cytosolic levels 
of Rpl13a snoRNAs (Figure 3.3 D and E). Thus, accumulation of Rpl13a snoRNAs in 
the cytosol can result from either acute or chronic knockdown of NXF3. This effect is 
specific for NXF3 and appears consistent across different cell types.  
 
3.2.4 Overexpression of NXF3 decreases cytosolic Rpl13a snoRNAs in 
cardiomyoblasts 
Our data are consistent with a model in which NXF3 function is required to maintain low 
cytoplasmic levels of the Rpl13a snoRNAs. To test whether NXF3 promotes movement 
of snoRNAs between the cytosol and nucleus, we overexpressed murine NXF3 by 
transiently transfecting NIH 3T3 murine fibroblasts with a GFP-tagged NXF3 construct 
(NXF3-GFP). As negative controls, we transfected plasmids expressing GFP alone or 
GFP-tagged NXF1 construct (NXF1-GFP) (Figure 3.4A). We consistently observed 
more efficient transfection with GFP compared to NXF3-GFP and NXF1-GFP, 
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suggesting that endogenous mechanisms serve to restrict the overall expression of 
NXF3 and NXF1. Nonetheless, compared to expression of GFP alone, expression of 
NXF3-GFP decreased cytosolic levels of the Rpl13a snoRNAs by 16-34% while there 
was no significant change in cytosolic Rpl13a snoRNAs after NXF1-GFP 
overexpression (Figure 3.4B and C). Additionally, we transiently transfected rat 
cardiomyoblasts with a non-tagged construct of NXF3. Comparable decreases in U32, 
U33 and U34 were observed between non-tagged and GFP-tagged NXF3 (Figure 
3.4D). Together with findings from knockdown of NXF3, our data suggest a model in 
which NXF3 promotes movement of snoRNAs from the cytoplasm to the nucleus and 
determines the distribution of the snoRNAs between these cellular compartments. 
 
3.2.5 NXF3 and NXF1 associate with snoRNAs  
Since NXF3 is a member of a nuclear RNA transporter family and genetic manipulation 
of NXF3 impacted Rpl13a snoRNA localization, we hypothesized that NXF3 may serve 
as a snoRNA transporter. A corollary of this hypothesis is that NXF3 should physically 
interact with the Rpl13a snoRNAs. We transiently transfected H9c2 rat cardiomyoblasts 
NXF3-GFP or GFP alone, and NIH 3T3 murine fibroblasts with NXF3-GFP, NXF1-GFP, 
or GFP alone and performed immunoprecipitation studies using a GFP antibody, or 
non-immune IgG as a control. Antibody directed against GFP efficiently and specifically 
pulled down GFP, NXF3-GFP, or NXF1-GFP, while no GFP, NXF3-GFP or NXF1-GFP 
was recovered in control IgG immunoprecipitations (Figure 3.5A and B). Real-time 
PCR quantification revealed a 7- to 10-fold increase in Rpl13a snoRNA association with 
immunoprecipitated NXF3-GFP compared to immunoprecipitated GFP in 
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cardiomyoblasts and 10- to 15-fold increase in fibroblasts (Figure 3.6A and B). 
Interestingly, real-time PCR quantification revealed NXF1-GFP also associated with the 
Rpl13a snoRNAs at similar levels as NXF3-GFP in NIH 3T3 murine fibroblasts.  
Although only knockdown and overexpression of NXF3 alered snoRNA localization 
(Figures 3.3 and 3.4), our data indicate that both NXF family members are capable of 
associating with the Rpl13a snoRNAs.  
 
We used RNA-sequencing to determine whether NXF3 associates only with Rpl13a 
snoRNAs or with snoRNAs more broadly. We collected RNA from cell lysates before 
immunoprecipitation (input) and RNA from immunoprecipitates (pulldown) of NIH 3T3 
murine fibroblasts transfected with NXF3-GFP. Because most snoRNAs lack polyA tails 
and do not efficiently prime with random hexamers, they are not well represented in 
standard libraries prepared using approaches suitable for mRNAs and larger non-
coding RNAs 92. To achieve broad coverage of snoRNAs from both input and pulldown 
samples, we size-selected RNAs from 30 to 375 nucleotides, a range that would 
exclude most miRNAs and include most snoRNAs. Libraries were prepared using an 
Illumina small RNA library preparation kit, sequenced, and aligned to mm9 Refseq 
Transcripts. We focused our analyses on the non-rRNA sequences, which accounted 
on average for 55% reads in both input and pulldown samples (Table 3.6A). Greater 
than 98% of non-rRNA reads in the input and pulldown samples aligned to snoRNAs, as 
expected (Table 3.6B). In addition to the Rpl13a snoRNAs, NXF3 pulldown recovered 
many other snoRNAs (Table 3.6C), most of which belonged to the box C/D class of 
snoRNAs, known to be most abundant 93-95. Approximately 6% of reads in both input 
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and pulldown aligned to box H/ACA snoRNAs. Due to the methods required to capture 
snoRNA sequences in library preparation, it was not possible to determine whether 
NXF3 specifically enriches for snoRNAs over other classes of RNAs. Nonetheless, lack 
of significant enrichment of specific snoRNA species in pulldown relative to input 
snoRNAs, indicates that NXF3 broadly associates with this class of small RNAs and 
does not have specificity for the Rpl13a snoRNAs or other particular species (Table 
3.6C). To validate association with additional box C/D and box H/ACA snoRNAs, we 
transfected NIH 3T3 fibroblasts with NXF3-GFP or NXF1-GFP or GFP as control, 
immunoprecipitated with antibody to GFP, and performed RT-qPCR on recovered RNA 
for abundant snoRNAs for which stem-loop primers were successfully designed. Each 
of the snoRNAs tested showed similar enrichment in NXF3-GFP and NXF1-GFP 
pulldown over GFP pulldown, with the exception of SNORA52 (Figure 3.6C). Together, 
our data indicate that NXF3 and NXF1 are capable of associating with a broad range of 
snoRNAs. Nonetheless, gain- and loss-of-function analyses indicate that only NXF3 
functions as a snoRNA nucleocytoplasmic transporter.  
 
3.3 CONCLUSIONS 
The endogenous substrates for NXF3, a member of a family of RNA transport proteins, 
are not well characterized. We show that NXF3 and NXF1 associate with the Rpl13a 
snoRNAs, along with many box C/D and box H/ACA snoRNAs. We demonstrate that 
gain- and loss-of-function of NXF3, but not NXF1, alters the subcellular distribution of 
snoRNAs encoded within the Rpl13a locus. Together, our data are most consistent with 
a model in which snoRNAs cycle between the nucleus and cytoplasm and NXF3 
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efficiently imports snoRNAs from the cytoplasm to the nucleus, a function that helps to 
maintain low levels of snoRNAs in the cytoplasm under normal homeostatic conditions.  
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3.4 FIGURES AND TABLES 
 
  
FIGURE 3.1. Knockdown of NXF3 protects against lipotoxic cell death in 
endothelial cells. Human umbilical vein endothelial cells (HUVECs) were transduced 
with non-targeting (ctrl) or NXF3-targeting shRNA. A. Viability following 48 h incubation 
in media containing 500 µM palmitate. Mean (+ SE) for n = 4. B. RT-qPCR 
quantification of NXF3 mRNA relative to Rplp0 (relative units, RU). Mean (+ SE) for n = 
3. C. Representative western blot analysis (above) of NXF3 and HSP90 expression or 
total protein by Ponceau staining with quantification of mean (+SE) NXF3 expression 
relative to HSP90 or total protein from n = 3 experiments. *, p < 0.05; **, p < 0.01 for 
NXF3 knockdown vs. ctrl 
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FIGURE 3.2. NXF3 knockdown alters Rpl13a snoRNA localization under basal 
growth conditions in endothelial cells. HUVECs were transduced with ctrl or NXF3-
targeting shRNA. A. RT-qPCR quantification of Rpl13a snoRNAs (relative to Rplp0) in 
cytosolic or total extracts. Mean (+SE) for n = 4 independent experiments. B. 
Representative western analysis of cytosolic and non-cytosolic fractions for cytosolic 
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(HSP90; α-tubulin, TUB) and nuclear (nucleophosmin, NPM) markers. C. Cells were 
untreated or treated with 1mM H2O2 for 4h. RT-qPCR quantification of Rpl13a snoRNAs 
in cytoplasmic extracts relative to Rplp0 and normalized to levels in untreated ctrl 
shRNA-transduced cells. Mean (+SE) for n = 3. D. Quantification of superoxide in 
untreated ctrl and NXF3-knockdown cells by dihydroethidium (DHE) staining. Mean 
relative fluorescence (RU) + SE for n = 3. E. Representative immunofluorescence 
staining for NPM and DAPI staining without or following treatment with H2O2. Scale bar, 
50 µM. *, p < 0.05 for NXF3 vs. ctrl shRNA transduced cells; #, p < 0.05 for H2O2 
treated vs. untreated; ns, non-significant 
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FIGURE 3.3 Knockdown of NXF3 alters Rpl13a snoRNA localization in 
cardiomyoblasts. A. Domain structures of NXF1 and NXF3 showing RNA binding 
domain (RBD), four leucine-rich repeats (4x LRR), sequence with similarity to nuclear 
transport factor 2 (NTF2-like, involved in p15binding), ubiquitin-associated-like domain 
(UBA), nuclear localizing sequence (NLS), nuclear export sequence (NES), and CRM1 
binding region. B-D. H9c2 cardiomyoblasts were transfected with scrambled siRNA 
(ctrl) or two independent siRNAs targeting NXF3 (B, C) or NXF1 (D, E). RT-qPCR 
quantification of NXF3 and NXF1 in total RNA (B, D, left graphs) and Rpl13a snoRNAs 
in cytosolic RNA (B, D, right graphs) are reported as means (+SE) for n = 3 
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independent experiments. Representative western analysis (C, E) of cytosolic and non-
cytosolic fractions for cytosolic (HSP90, TUB) and nuclear (NPM) markers as controls 
for panels B and D, respectively. *, p < 0.05 
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FIGURE 3.4. Overexpression of NXF3 alters Rpl13a snoRNA localization in 
fibroblasts. NIH 3T3 fibroblasts were transfected with control plasmid (GFP) or plasmid 
encoding NXF3-GFP or NXF1-GFP. A. Representative western analysis and flow 
cytometric analysis following transfection. Mean (+SE) for n = 3. B. RT-qPCR of 
cytosolic Rpl13a snoRNAs. Mean (+SE) for n = 3. C. Representative western analysis 
of cytosolic and non-cytosolic fractions for cytosolic (HSP90, TUB) and nuclear (NPM) 
markers. D. RT-qPCR quantification of murine NXF3 in total RNA following transfection 
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of rat cardiomyoblasts (left graph) and corresponding quantification of Rpl13a snoRNAs 
in cytosolic RNA (right graph) are reported as means (+SE) for n = 3. *, p < 0.05. 
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FIGURE 3.5. NXF3- and NXF1-GFP can be immunoprecipitated using α-GFP. 
Immunoprecipitation with α-GFP or rabbit IgG as control was analyzed by western blot 
analysis using α-GFP. A. H9c2 cardiomyoblasts were transfected with control plasmid 
(GFP) or plasmid encoding NXF3-GFP. B. NIH3T3 fibroblasts were transfected with 
control plasmid (GFP) or plasmid encoding NXF3-GFP. C. NIH 3T3 fibroblasts were 
transfected with control plasmid (GFP) or plasmid encoding NXF1-GFP.  
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Figure 3.6. NXF3 and NXF1 associate with snoRNAs. A. Co-immunoprecipitating 
RNA was isolated and quantified by RT-qPCR for Rpl13a snoRNAs in H9c2 
cardiomyoblasts transfected with control plasmid (GFP) or plasmid encoding NXF3-
GFP. B,C. NIH3T3 fibroblasts were transfected with control plasmid (GFP) or plasmid 
encoding NXF3-GFP or NXF1-GFP. Co-immunoprecipitating RNA was isolated and 
quantified by RT-qPCR for Rpl13a snoRNAs (B) and selected box C/D and box H/ACA 
snoRNAs (C). Graphs report enrichment in NXF3-GFP-transfected or NXF1-GFP--
transfected cells over GFP-transfected cells. Means (+SE) for n = 3 independent 
experiments. *, p < 0.05 
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Table 3.6A Quality of RNA Sequencing Data 
 
Total 
reads 
Avg 
quality % G/C 
Total 
aligned 
% 
Aligned % rRNA 
Input 1 12622611 36.56 42.81 6914155 54.78 49.32 
Input 2 8494636 36.53 43.23 3561964 41.93 36.13 
Input 3 15845764 36.57 42.99 7717165 48.70 42.95 
Pulldown 1 3321562 36.63 43.40 1498556 45.12 38.85 
Pulldown 2 19470767 36.55 42.52 12639529 64.92 59.51 
Pulldown 3 13412207 36.55 42.45 6330452 47.20 43.59 
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Table 3.6B Distribution of Non-Ribosomal RNA Reads 
RNA Input (%) Pulldown (%) Significance 
C/D snoRNA 92.45 ± 0.93 91.92 ± 1.69 NS 
H/ACA snoRNA 6.26 ± 0.79 6.98 ± 1.50 NS 
lncRNA 0.24 ± 0.04 0.33 ± 0.08 NS 
miRNA 0.27 ± 0.02 0.19 ± 0.07 NS 
mRNA 0.76 ± 0.09 0.59 ± 0.13 NS 
Other 0.02 ± 0.00 0.00 ± 0.00 NS 
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Table 3.6C Most Abundant Immunoprecipitating snoRNAs 
Gene ID LSMean (Pulldown) 
LSMean 
(Input) 
Enrichment 
(pulldown/input) FDR P-value Significance 
Snord55 421533.33 422930.00 1.00 1.00 0.84 NS 
Snord44 299548.00 218320.33 1.37 0.99 0.87 NS 
Z23 229492.67 218334.00 1.05 0.99 0.56 NS 
Snord24 208143.67 156536.67 1.33 0.99 0.90 NS 
Snord2 144321.67 150285.33 0.96 1.00 0.64 NS 
Snora48 120987.00 114743.00 1.05 0.99 0.87 NS 
Snord45 97189.00 82084.33 1.18 0.99 0.77 NS 
Z19 76795.67 86895.67 0.88 0.99 0.57 NS 
Z15 70041.33 78718.67 0.89 0.99 0.64 NS 
Snord14e 56763.00 51011.67 1.11 0.99 0.90 NS 
Snord4a 50187.00 32887.00 1.53 1.00 0.91 NS 
Snord96a 29898.00 36448.00 0.82 1.00 0.53 NS 
Snord45c 26526.00 17509.67 1.51 0.99 0.99 NS 
Snord74 23828.33 20331.67 1.17 0.99 0.74 NS 
Snord32a 23639.33 36071.67 0.66 1.00 0.62 NS 
Snord14d 18182.33 14849.67 1.22 0.99 0.79 NS 
Snord14c 14650.00 11996.67 1.22 0.99 0.77 NS 
Snord73 11345.33 10193.33 1.11 0.99 0.61 NS 
Snord34 10821.67 9770.33 1.11 1.00 0.61 NS 
Snord95 9882.33 7793.67 1.27 1.00 0.84 NS 
Snord1b 8164.00 8715.67 0.94 1.00 0.49 NS 
Snord35a 5050.33 7777.33 0.65 1.00 0.43 NS 
Snord113 4508.67 5383.67 0.84 0.99 0.81 NS 
Snord82 4491.33 3655.33 1.23 1.00 0.97 NS 
Snord104 3567.00 2764.67 1.29 1.00 0.98 NS 
DQ267100 2406.67 3323.33 0.72 0.99 0.50 NS 
Snord100 2392.67 2097.33 1.14 1.00 0.76 NS 
Snord1c 2302.00 2378.67 0.97 1.00 0.42 NS 
Snord12 2044.33 862.67 2.37 1.00 0.34 NS 
Snord33 1497.33 881.00 1.7 1.00 0.87 NS 
Snord15b 1280.00 1128.67 1.13 1.00 0.99 NS 
Snord123 1268.67 1322.00 0.96 1.00 0.45 NS 
Rnu73b 980.33 984.00 1.00 1.00 0.47 NS 
DQ267102 963.33 1123.33 0.86 0.99 0.74 NS 
Snord92 746.67 466.00 1.60 1.00 0.88 NS 
Snord37 650.00 674.67 0.96 0.99 0.61 NS 
AF357426 647.33 366.67 1.77 0.99 0.98 NS 
AF357425 505.67 525.67 0.96 0.99 0.81 NS 
Snord15a 478.00 545.67 0.88 1.00 0.69 NS 
AF357355 317.33 388.00 0.82 0.99 0.87 NS 
Snord110 297.33 158.00 1.88 1.00 0.62 NS 
Snora24 271.51 742.24 0.37 1.00 0.07 NS 
Z21 220.00 144.67 1.52 0.99 0.93 NS 
Gm24148 198.00 134.00 1.48 1.00 0.78 NS 
Snord22 189.33 340.00 0.56 1.00 0.24 NS 
Snora52 180.00 212.67 0.85 1.00 0.42 NS 
Snora16a 163.33 144.00 1.13 1.00 0.75 NS 
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CHAPTER FOUR: 
NXF3 as a point of regulation of transport 
 
4.1 INTRODUCTION 
Eukaryotic cells are divided into distinct compartments that have specific functions. This 
compartmentalization is important in determining the environments in which proteins 
and RNA operate. The localization of proteins and RNA within the cell can impact their 
functions. Therefore, transport between organelles and the resulting subcellular 
distribution is tightly regulated 96. An understanding of the regulation of the 
nucleocytplasmic transport of NXF3 and the snoRNAs, may provide insights into 
snoRNA roles outside of the nucleus.  
 
Forskolin (FSK) is a labdane diterpene drug that activates adenylyl cyclase, leading to 
an increase in levels of intracellular cyclic AMP 97. Protein kinase A (PKA) activation is 
dependent on cyclic AMP, thus allowing the catalytic subunits of PKA to phosphorylate 
many substrate proteins. The resulting phosphorylation of proteins can result in their 
translocation. For example, phosphorylation can increase the affinity between cargo and 
its specific import factor, thus increasing nuclear import. Additionally, phosphorylation of 
a protein can induce a conformational change that exposes an NLS. It is not known 
whether FSK impacts snoRNA trafficking or the function of NXF3 through 
phosphorylation. However, it is important to note that forskolin can also activate 
exchange proteins activated by cAMP and activate calcium channels 98-101.  
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Our work has shown that distribution of snoRNAs between the nucleus and cytoplasm is 
perturbed by treatment with doxorubicin (DOX). DOX is an anthracycline chemotherapy 
drug that induces high levels of reactive oxygen species (ROS) 47,83.  The mechanism 
whereby ROS in general or DOX in specific alters distribution of snoRNAs is not known. 
 
The experiments described below were undertaken to characterize the effects of FSK 
and DOX on snoRNA localization and to determine whether effects of these agents may 
be mediated through the actions of NXF3.   
 
4.2 RESULTS 
4.2.1 Forskolin decreases cytosolic Rpl13a snoRNAs and increases NXF3-Rpl13a 
snoRNA association 
Treatment of H9c2 cardiomyoblasts or NIH 3T3 fibroblasts for 1 h with FSK significantly 
decreased cytosolic Rpl13a snoRNA levels compared to DMSO-treated controls 
(Figure 4.1). To test whether FSK affects NXF3 localization or its association with 
snoRNAs, we transfected NIH 3T3 fibroblasts with a plasmid for expression of NXF3-
GFP. Similar to our findings with untransfected cells, and independent of the effects of 
NXF3 overexpression itself, cells over-expressing NXF3-GFP had decreased cytosolic 
snoRNA abundance following 1 h treatment with FSK (Figure 4.2 A and B). Moreover, 
FSK increased association of NXF3-GFP with the Rpl13a snoRNAs (Figure 4.2C). 
Concomitantly, immunofluorescence microscopy revealed increased nuclear localization 
of NXF3-GFP (Figure 4.2D). Together these observations are consistent with a model 
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of NXF3-mediated trafficking of snoRNAs from the nucleus to the cytoplasm that is 
regulated by FSK.  
 
4.2.2 NXF3 phosphorylation does not change during forskolin treatment  
FSK is a natural compound that activates cyclic AMP signaling through both PKA-
dependent and PKA-independent mechanisms that could lead to downstream 
phosphorylation cascades. Moreover, cAMP regulation of nucleocytoplasmic transport 
can be mediated through post-translational modifications of transporters, such as 
phosphorylation. Using algorithms for prediction of phosphorylation sites, we identified 
several potential sites for phosphorylation by PKA and other kinases 
[http://kinasephos2.mbc.nctu.edu.tw/]. We performed an immunoprecipitation of NXF3-
GFP before and after FSK treatment. Monoclonal antibodies specific for threonine-, 
serine-, or tyrosine-phosphorylation sites was used to determine whether NXF3-GFP 
phosphorylation levels change after FSK treatment. While each of these antiphospho-
antibodies recognizes immunoprecipitated NXF3-GFP, we did not detect any significant 
changes in phosphorylation levels after FSK treatment (Figure 4.3).  
 
4.2.3 Doxorubicin increases cytosolic Rpl13a snoRNAs and decreases NXF3-
Rpl13a snoRNA association 
Previously, we showed that treatment of cells with the chemotherapy drug doxorubicin 
(DOX) induces nucleolar stress and increases cytosolic Rpl13a snoRNAs 47. We 
hypothesized that DOX treatment might also regulate association between NXF3-GFP 
and the Rpl13a snoRNAs. As observed previously in untransfected cells 45,47, treatment 
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with DOX for 1 h increased cytosolic snoRNA levels in NXF3-GFP overexpressing cells 
(Figure 4.4 A and B). Furthermore, DOX decreased association between NXF3-GFP 
and the Rpl13a snoRNAs (Figure 4.4C). Although the wide fluorescence emission 
range of DOX confounds immunofluorescence microscopy approaches, analysis of 
subcellular fractions of NXF3-GFP expressing cells revealed that the drug decreases 
nuclear localization of NXF3 (Figure 4.4D). Thus, a treatment that promotes 
cytoplasmic accumulation of snoRNAs also perturbs localization of NXF3 and its 
association with snoRNA cargo. 
 
4.2.4 Forskolin effect on snoRNA localization is dependent on NXF3 
To determine whether the FSK- or DOX-induced changes in localization of Rpl13a 
snoRNAs were dependent on NXF3, H9c2 rat cardiomyoblasts were transiently 
transfected with siRNA to knockdown NXF3 (Figure 4.5A and C) and then treated with 
FSK or DOX. Although FSK decreased cytosolic Rpl13a snoRNAs as expected in 
control siRNA-transfected cells, this effect was abrogated when NXF3 was knocked 
down (Figure 4.5B). In contrast, DOX-induced increases in cytosolic U32a, U33, and 
U34 were preserved in the setting of knockdown of NXF3 (Figure 4.5D). As reported 
previously, DOX did not cause cytosolic accumulation of U35a 47. Taken together, our 
data are most consistent with a model in which FSK action to diminish cytoplasmic 
snoRNAs is dependent on NXF3. 
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4.3 CONCLUSIONS 
Our studies provide new evidence that FSK regulates the association of snoRNAs and 
the transport protein, NXF3, as well as the trafficking of both snoRNAs and NXF3. 
Furthermore, NXF3 is required for acute regulation of nuclear snoRNA import by FSK. 
On the other hand, lack of dependence of DOX-stimulated snoRNA export on NXF3 
suggests that this transport limb may not depend on NXF3. This data suggest a model 
in which snoRNAs are continuously cycled between the nucleus and cytosol under 
basal conditions. NXF3 efficiently returns the snoRNAs back to the nucleus. FSK 
treatment increases the association between NXF3 and the snoRNAs, and signals the 
NXF3-snoRNA complex to increase its localization into the nucleus, thus depleting the 
cytosolic levels of snoRNAs. While DOX treatment raises cytosolic levels of snoRNAs, 
this function appears to be indpenedent of NXF3 function (Figure 4.6).  
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4.4 FIGURES 
 
 
Figure 4.1 Forskolin decreases cytosolic Rpl13a snoRNA levels. H9c2 
cardiomyoblasts (A, B) and NIH 3T3 fibroblasts (C, D) were treated with 10 µM forskolin 
(FSK) or vehicle (DMSO) for 1 h. A, C. Quantification of cytosolic Rpl13a snoRNAs 
relative to Rplp0 by RT-qPCR. Mean (+SE) for n = 3 independent experiments B, D. 
Representative western analysis of cytosolic and non-cytosolic fractions for cytosolic 
(HSP90, TUB) and nuclear (NPM) markers. *, p < 0.05 
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Figure 4.2 Forskolin increases NXF3-GFP-snoRNA association and nuclear 
localization of NXF3-GFP. NIH 3T3 fiboroblasts were transfected with control plasmid 
(GFP) or plasmid encoding NXF3-GFP and subsequently treated with vehicle (DMSO) 
or 10 µM FSK for 1 h. A. Cytosolic Rpl13a snoRNAs were quantified by RT-qPCR 
relative to Rplp0 in DMSO treated cells. Mean (+SE) for n = 3 independent experiments. 
B. Representative western analysis of cytosolic and non-cytosolic fractions for cytosolic 
(HSP90, TUB) and nuclear (NPM) markers. C. Following immunoprecipitation with α-
GFP, Rpl13a snoRNAs were quantified by RT-qPCR. Graph reports snoRNA 
abundance in immunoprecipitates from NXF3-GFP-transfected cells relative to GFP-
transfected controls. Mean (+SE) for n = 3 independent experiments. D. Representative 
mmunofluorescence micrographs show NXF3-GFP localization. Graph reports summary 
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immunofluorescence data from n = 3 independent experiments. Cells were counted 
from 20 independent fields per treatment. Scale bar, 50 µM. *, p < 0.05. 
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Figures 4.3 Forskolin does not change NXF3-GFP phosphorylation levels. NIH 3T3 
fibroblasts were transfected with a plasmid encoding NXF3-GFP and compared to 
untreated, non-transfected cells. Transfected cells were treated with or without 10 µM 
FSK for 1 h. A. Representative western blot of immunoprecipitation with α-GFP was 
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analyzed using α-GFP to demonstrate efficient pulldown of NXF3-GFP. B-D. 
Representative western blots of immunoprecipitation with α-GFP was analyzed using α-
GFP or specified anti-phospho-threonine (B), anti-phospho-serine (C), and anti-
phospho-tyrosine (D) antibodies.  
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Figure 4.4 Doxorubicin increases cytosolic snoRNAs and decreases NXF3 
association with Rpl13a snoRNAs. H9c2 cardiomyoblasts were transfected with 
plasmids encoding NXF3-GFP or GFP as control and then were untreated (UT) or 
treated with 20 µM doxorubicin (DOX) for 1 h. A, B. Cytosolic snoRNAs quantified by 
RT-qPCR relative to Rplp0 in NXF3-GFP-transfected cells. Graph (A) shows mean 
(+SE) for n = 4 independent experiments. Representative western analysis of cytosolic 
and non-cytosolic fractions for cytosolic (HSP90, TUB) and nuclear (NPM) markers (B). 
C. Following immunoprecipitation with α-GFP, Rpl13a snoRNAs were quantified by RT-
qPCR. Graph reports snoRNA abundance in immunoprecipitates from NXF3-GFP-
transfected cells relative to GFP-transfected controls. Mean (+SE) for n = 3. D. NXF3-
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GFP localization before and after DOX treatment assessed by digitonin extraction. 
Representative western analysis and graphs showing summary densitometric analysis 
from n = 3 independent experiments. *, p < 0.05; **, p < 0.0001 
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Figure 4.5 Forskolin effect on snoRNA localization is dependent on NXF3. H9c2 
cardiomyoblasts were transfected with scrambled siRNA (ctrl) or siRNA targeting NXF3 
and subsequently treated for 1 h with 10 µM FSK (A, B) or 20 µM DOX (C, D). A, C. 
RT-qPCR quantification of total NXF3 relative to Rplp0. B, D. RT-qPCR quantification of 
cytosolic Rpl13a snoRNAs relative to Rplp0. Graphs show mean (+SE) for n = 3 
independent experiments. * p < 0.05; ** p < 0.01 
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Figure 4.6 Model for NXF3 function. SnoRNAs cycle between the nucleus and 
cytoplasm under homeostatic conditions. NXF3 functions as an importer, efficiently 
returning snoRNAs to the nucleus and maintaining a high concentration of snoRNAs in 
the nucleus relative to the cytoplasm. FSK treatment enhances return of NXF3-snoRNA 
complexes to the nucleus, further depleting cytosolic levels of snoRNAs.  
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CHAPTER FIVE: 
Summary and Discussion 
 
5.1 Summary 
There is evidence for a growing number of non-canonical roles for snoRNAs. The 
Rpl13a snoRNAs have been shown to mediate the cellular response to metabolic stress 
in vitro and in vivo 45,61. Moreover, these  and other snoRNAs accumulate in the cytosol 
in response to lipotoxic stress and general oxidative stress 45,47. The mechanisms 
through which snoRNAs act in metabolic stress responses and their RNA targets in this 
response are not known. However, it is possible that movement of snoRNAs out of the 
nucleus during these stress response pathways enables snoRNAs to target RNAs in 
other cellular compartments, including mRNAs. Experimentally disrupting the 
nucleocytoplasmic trafficking of the snoRNAs could be used to probe the functions of 
snoRNAs in the cytosol. However, mechanisms that govern snoRNA localization and 
transport between the nucleus and cytoplasm are poorly understood. Herein, we 
demonstrate that the cytosolic accumulation of snoRNAs is regulated by enzyme 
NOX4D during doxorubicin treatment. We have also identified NXF3 as a potential 
snoRNA nucleocytoplasmic transporter.  
 
5.2 Cytosolic snoRNAs 
Previous studies using traditional methods like in situ hybridization and cell fractionation 
with detection by northern blotting have shown that snoRNAs localize solely in the 
nucleus within Cajal bodies and nucleoli, where they perform their canonical function of 
modifying snRNA and rRNA, respectively. Our experiments in which we coupled high 
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sensitivity methods of RT-qPCR or RNA-seq to cell fractionation approaches, 
demonstrate for the first time that a broad range of snoRNAs is easily detectable in the 
cytoplasm under basal, homeostatic conditions. The accumulation of snoRNAs in the 
cytoplasm after oxidative stress induced by DOX is rapid and significant. Prior studies 
demonstrated that independently transcribed, capped snoRNAs U3, U8 and U13 traffic 
between the nucleus and cytoplasm. We show that in addition to these snoRNAs, 
intronic, uncapped snoRNAs follow this itinerary and are present in the cytoplasm.  
 
Our data demonstrate that the localization of snoRNAs as a class is regulated at least in 
part by NOX and superoxide. Furthermore, our knockdown studies implicate nuclear 
localized NOX4D as a key regulator of the nuclear-cytosolic partitioning of Rpl13a 
snoRNAs. Under homeostatic conditions, most intronic snoRNAs localize in the 
nucleolus, suggesting that following synthesis these snoRNAs either remain within the 
nucleus, or if they traffic to the cytoplasm, they are efficiently returned to the nucleus. A 
model of tight regulation of cytosolic snoRNA levels is further supported by our lab’s 
prior observation that mutant cells with 50% reduction of nuclear Rpl13a snoRNAs 
maintain wild-type cytosolic levels of these snoRNAs 46. The rapid accumulation of 
snoRNAs in the cytosol following DOX treatment suggests that nuclear superoxide 
promotes redistribution of these snoRNAs into the cytosol. Together, these data 
suggest the nucleocytoplasmic trafficking of snoRNAs is highly regulated. Moreover, the 
presence of snoRNAs in the cytosol provides a new context in which these snoRNAs 
may function in potentially novel roles beyond the modifications of rRNAs and snRNAs.   
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5.3 NXF3 as a snoRNA transporter 
NXF family members have been identified based on sequence similarity and domain 
architecture that for most includes an amino terminal containing RNA binding domain 
(RBD), a p15/NXT-heterodimerization domain, and a carboxyl terminal domain involved 
in nuclear pore binding 102,103. The RBD is conserved within the NXF family, however it 
is poorly defined for NXF3 as the predicted RBD does not bind to RNA, while the 
corresponding domains in NXF1 and NXF2 are capable of binding RNA 104,105. The NXF 
family name implies that these proteins are primarily involved in nuclear export. Similar 
to NXF1, NXF3 is capable of associating with mRNA 67,73. Prior studies in which 
RNA/protein complexes were isolated in cells transfected with an HA-tagged form of 
NXF3 using oligo dT cellulose. The complexes indicated a specific interaction between 
poly(A) RNA and HA-NXF3, providing evidence for a role of NXF3 in nuclear export of 
mRNA. Furthermore, a leucine-rich NES was identified within NXF3 that recruits CRM1 
for its nuclear export activity 73.  
 
Our data support a model in which NXF3 also has a role in importing RNAs to the 
nucleus. Knockdown of NXF3 resulted in an increase of cytosolic Rpl13a snoRNAs 
while overexpression resulted in a decrease. This data implicated NXF3 as a nuclear 
importer, efficiently returning snoRNAs from the cytosol to the nucleus under basal 
conditions. On the other hand, knockdown and overexpression of a related family 
member, NXF1, did not alter localization of the Rpl13a snoRNAs. Our study is the first 
to explore the potential contribution of NXF family members to snoRNA trafficking. 
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Together, our data suggest a new role specific to NXF3 as a nuclear importer for 
snoRNAs. 
 
In both gain- and loss-of-function studies and in snoRNA binding studies, we compared 
NXF3 to NXF1. Although the effects of genetic manipulation on snoRNA localization 
were specific for NXF3, both family members are capable of binding the snoRNAs in co-
immunoprecipitations. Although the RNA binding domains of NXF3 are not well 
characterized, NXF1 contains three RNA binding domains: RNA recognition motif 
(RRM), leucine-rich repeat, and NTF2-like domain 70. The RRM has non-specific RNA 
binding activity 105. It is possible that under the conditions of our immunoprecipitations, 
the RRM is capable of binding snoRNAs, even if this family member does not alter 
snoRNA distribution in situ. Future structure-function studies of NXF3 that target RNA 
binding requirements will provide important insights into this proteins role in snoRNA 
trafficking. It will also be of interest to compare NXF3 function in snoRNA trafficking to 
NXF family members in addition to NXF1 
 
Some RNA export receptors directly bind to uncapped RNA targets, like miRNA and 
tRNA, while others require adaptor proteins like the cab binding complex (CBC) to bind 
to the caps of their target RNA, such as snRNA and mRNA 67. Intiguingly, the snRNA 
export receptors CRM1 and PHAX are required for the intranuclear transport of 
independently transcribed, capped snoRNAs 75. Whether CRM1 and PHAX function 
coordinately with NXF3 in snoRNA binding and movement between the nucleus and 
cytoplasm will be the subject of future studies.  
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While our data suggests that NXF3 regulates the localization of snoRNAs, the most 
direct way to demonstrate NXF3 acts as a snoRNA importer is to perform a nuclear 
import assay. However, this method has previously been established for proteins, not 
snoRNAs. We are currently developing a method with biotin-labeled snoRNAs and 
digitonin-permeablized cells. If successful, this method could also be extended to live-
cell imaging and determine the kinetics of snoRNA transport under different conditions, 
like FSK treatment. 
 
5.4 Regulation of NXF3-mediated snoRNA transport 
To probe the regulation of snoRNA transport, we treated cells with adenylyl cyclase 
activator FSK to increase intracellular levels of cyclic AMP. FSK treatment depleted 
cytosolic snoRNAs, an effect that is dependent on NXF3. The increase in NXF3-
snoRNA association and increase in nuclear localization of NXF3 suggested that the 
NXF3 import of snoRNAs is activated by FSK. On the other hand, DOX treatment 
increased cytosolic snoRNAs, decreased NXF3-snoRNA association and decreased 
nuclear localization of NXF3. However, the DOX effect was not dependent on NXF3. 
Together, our data suggest a model in which NXF3 plays a critical role in the return of 
snoRNAs from the cytoplasm to the nucleus, a pathway activated by FSK, but does not 
participate in DOX-stimulated snoRNA export.  
 
FSK activates cyclic AMP signaling through both PKA-dependent and PKA-independent 
mechanisms 98-101. This could lead to altered post-translational modifications, such as 
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phosphorylation of NXF3 or other proteins which function in snoRNA transport. Although 
examination of the NXF3 primary sequence suggests a number of potential 
phosphorylation sites, FSK did not change NXF3 phosphorylation, as determined using 
a panel of α-phospho-tyrosine, α-phospho-serine, and α-phospho-threonine antibodies. 
It is possible that the available antibodies lack appropriate specificity or that NXF3 is not 
a direct target of FSK. Structure function and proteomics studies will be necessary to 
address these possibilities. Furthermore, it is likely that NXF3 is acting in a complex of 
proteins similar to other RNA transport pathways and may be associated with another 
protein is phosphylated in response to FSK. In the future, immunoprecipitations could 
be coupled to mass spectrometry analyses to identify potential NXF3 protein partners. 
To confirm NXF3 transport is regulated by cyclic AMP, other inducers of intracellular 
levels of cyclic AMP like cholera toxin, phosphodiesterase inhibitors, or PKA inhibitors 
could be used 106. Additionally, since FSK can activate cyclic AMP signaling through 
PKA-independent mechanisms, treating cells with PKA inhibitors could help narrow 
down the mechanism regulating NXF3 transport.  
 
Our data have shown that the snoRNAs interact with NXF1 as well as NXF3. Given that 
knockdown and overexpression of NXF1 Does not affect cytosolic snoRNA levels, it will 
be of interest to test whether NXF1 association with the Rpl13a snoRNAs changes after 
FSK or DOX treatment, similar to NXF3. A finding that NXF1-snoRNA association is 
unchanged by FSK or that NXF1 knockdown has no effect on FSK-induced decreases 
in cytosolic snoRNAs, would provide further evidence of specificity for NXF3 function in 
snoRNA transport. 
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5.5 NXF3 and lipotoxicity 
The physiological role of NXF3 is unclear. NXF3 has previously been shown to be 
dispensable for spermatogenesis, but its role in metabolic stress has not been 
investigated 107. It would be interesting to develop a NXF3 knockdown mouse model 
and determine whether tissues are protected from metabolic stress such as lipid 
overload. Localization of snoRNAs could be measured from tissues isolated from this 
mouse model to confirm that loss of NXF3 alters snoRNA localization 
 
Knockdown of NXF3 confers resistance to lipotoxicity, a process dependent on 
snoRNAs from the Rpl13a locus. Loss of NXF3 also alters distribution of these 
snoRNAs at baseline and prevents acute increase in cytosolic levels with lipotoxicity. 
The abundance of cytoplasmic Rpl13a snoRNAs in NXF3-knockdown cells is 
comparable to the levels achieved in control cells following acute lipotoxic exposure. 
This suggests that the dynamic change in cytosolic snoRNAs, rather than the absolute 
cytoplasmic levels of these non-coding RNAs is a key contributor to lipotoxic injury.  
The role of cytosolic snoRNAs is still unknown. Rpl13a snoRNA knockdown cells had 
no change in methylation of their predicted rRNA targets, therefore suggesting a 
noncanonical targets for the Rpl13a snoRNAs. In situ hybridization studies revealed the 
Rpl13a snoRNAs localized in puncta in the cytosol after metabolic stress (CITE 
MICHEL 2011). It is possible that the snoRNAs are transported to specific organelles 
from the nucleus by NXF3. Future experiments should focus on determination of the 
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precise distribution and itinerary of snoRNAs once they leave the nucleus. Identifying 
the cytosolic localization could provide insight in the role of snoRNAs outside of the 
nucleus. A complete understanding of this new snoRNA biology requires further 
dissection of snoRNA trafficking and its regulation. Our identification of a role for NXF3 
in regulated snoRNA trafficking represents a first step in this important direction.  
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CHAPTER SIX: 
Materials and Methods 
 
Materials—Digitonin, forskolin (FSK), phenylmethanesulfonyl fluoride (PMSF), 
cOmplete protease inhibitor cocktail, and hydrogen peroxide (H2O2) were from Sigma. 
Protein A Dynabeads, TURBO DNAse, and dihydroethidium (DHE) were from Thermo 
Fisher Scientific. Doxorubicin (DOX) was from Cayman Chemical. TRIzol LS and 
SUPERase-IN RNAse inhibitor was from Life Technologies. Dithiothreitol (DTT) was 
from CalBiochem and β-mercaptoethanol (BME) from Sigma. Laemmli Sample Buffer 
was from Bio-Rad. 
 
Cells—H9c2 cardiomyoblasts and NIH3T3 fibroblasts were from American Type Culture 
Collection. Telomerase-immortalized human umbilical vein endothelial cells (HUVECs) 
were a gift from Judah Folkman’s laboratory (Harvard Medical School) 108 H9c2 and 3T3 
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat 
inactivated fetal bovine serum (H9c2) or 10% calf serum (NIH3T3). HUVECs were 
maintained in endothelial cell growth medium (Lonza).  DOX (20 µM for 1 h), FSK (10 
µM for 1h), or H2O2 (1 mM, 4h) were added to media as indicated. Cell viability was 
determined using CellTiter-Glo Luminescent Cell Viability Assay (Promega). Basal 
cellular ROS was detected by staining cells (100,000 cells per well of 12-well dishes) 
with 10 µM DHE and detection using a microplate fluorescence reader (Tecan). Cells 
were transfected with plasmid DNA peGFP-1 (Clontech) and NXF3-GFP (gift from the 
Sun lab) 109 using Lipofectamine 2000 (Life Technologies) and with siRNAs (Life 
Technologies Silencer Select) using RNAiMax (Life Technologies), according to the 
	 76 
manufacturers’ protocols. Flow cytometric analysis of transfected cells assessed 
fluorescence on 104 cells/sample. 
 
shRNA screen—The shRNA screen was performed using a Decode Human GIPZ 
Lentiviral shRNAmir Library (Thermo Scientific). Immortalized HUVECs were 
transduced with lentiviral shRNA pools at MOI 0.1 then selected using puromycin. 
Puromycin-resistant cells were then treated with 500 µM palmitate for 48 h. After 
removing palmitate, cells were grown to form colonies in standard media. Colonies were 
hand-picked and re-tested for viability following lipotoxic exposure. For this, cells were 
plated in 96-well plate in triplicates (1000 cells per well) and treated with 500 µM 
palmitate for 24h. Cells transduced with non-targeting shRNA viral particles were used 
as negative control. Colonies with significantly greater viability than control cells were 
selected for further analysis. Genomic DNA was isolated from palmitate-resistant cells, 
and PCR was used to amplify barcodes corresponding to specific shRNAs for 
sequencing. Sequences were compared to the Decode shRNA libraries or analyzed 
using BLAST to identify the knocked down genes.  
 
Subcellular Fractionation—For fractionation by detergent extraction, cell pellets were 
incubated in digitonin buffer (150mM NaCl, 50mM HEPES pH 7.4, digitonin 100µg/mL, 
EDTA 5mM, and SUPERase-In RNase inhibitor 0.1U/µL) for 10 min and centrifuged for 
10 min at 2000g to yield a cytoplasmic supernatant and non-cytoplasmic pellet 
containing membranes and nuclei 110. 
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RNA isolation and quantitative real-time PCR—Total RNA was isolated from 
cytoplasmic or non-cytoplasmic fractions and from immunoprecipitates using TRIzol LS 
according to manufacturer’s protocol (Life Technologies). cDNA was synthesized with 
SuperScript III First-strand Synthesis System (Invitrogen) using oligo-dT priming for 
mRNAs and target-specific stem-loop priming snoRNAs 45. qPCR was performed using 
PerfeCTa SYBR Green SuperMix (Quantabio). Relative quantitation of target transcript 
expression was calculated using the ddCT method using Rplp0 as an endogenous 
control on an ABI 7500 Fast Real-time PCR system. 
 
Immunoprecipitation—Cells were sonicated in 50 mM Tris pH 8.0, 150 mM NaCl, 2 
mM EDTA, 0.5% NP40 containing 1X cOmplete protease inhibitor cocktail, 1 mM 
PMSF, and 0.1U/µl RNase inhibitor SUPERase-In. After treatment with 0.3U/µl TURBO 
DNase, insoluble material was removed by centrifugation at 20,000 x g for 10 min at 
4°C. Lysate was incubated with α-GFP (2.5mg/mL) and Protein A Dynabeads for 4 h at 
4°C. Complexes were washed four times with lysis buffer. Protein was eluted by 
incubation in 2X Laemmli Sample Buffer for western analysis, and RNA was eluted by 
incubation in TRIzol LS. 
 
RNA sequencing—For cytosolic snoRNA sequencing experiments, H9c2 cells from 3 
independent experiments were treated as indicated, cytosol was recovered by detergent 
extraction, and total RNA was isolated using TRIzol LS followed by Qiagen RNeasy 
miRNA clean up. Input and immunoprecipitated RNA from 3T3 cells from 3 independent 
experiments was isolated and concentrated using RNA Clean & Concentrator-5 (Zymo 
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Research). Indexed RNA-sequencing libraries were made using the Illumina TruSeq 
small RNA kit. Libraries were amplified with 14 cycles of PCR, pooled, and separated by 
PAGE. Products with sizes 30-375 nucleotides were excised and collected from the gel. 
Sequencing was performed using an Illumina HiSeq 2500. Demultiplexed data were 
analyzed using Partek Flow (build version 6.0.17.0305 Copyright ©; 2017 Partek Inc., 
St. Louis, MO, USA). H9c2 sequences were uploaded to Galaxy. Sequences were 
evaluated for quality by FASTQC, trimming was applied to reject scores of <20, and 
sequences were clipped to remove adapter sequence. Sequences were aligned to the 
rat genome (rn4, Bowtie for Illumina, default settings) and aligned reads were exported 
to Partek Genomics Suite (v.6.6) for annotation and quantitative analysis using the rat 
genome build that contains snoRNAs (Ensembl Build e69, RGSC3.4.69).  
For NXF3 pulldown studies in NIH 3T3 cells, sequences were evaluated for quality and 
trimmed to remove adapter sequence. A custom Linux script was used to remove 
murine ribosomal sequences according to the Illumina iGenome murine genome 
annotation. Remaining sequences were aligned to the murine genome (mm9 Refseq 
Transcript 2016-08-01, Bowtie for Illumina, default settings) and aligned reads were 
quantified, normalized and annotated. Analysis was limited to genes with >100 aligned 
reads. A step-up FDR of 0.05 was considered significant.  
 
Immunoblots—Protein in total, cytoplasmic and non-cytoplasmic fractions was 
quantified by bicinchoninic assay (BCA, Thermo Fisher Scientific), separated by SDS-
PAGE, and immunoblotted. Detection for human nuclear export factor 3 (NXF3; Abcam 
ab76430, 1:500), GFP (Abcam ab290, 1:5000), heat shock protein 90 (HSP90; Enzo 
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SPA-846, 1:1000), α-tubulin (α-TUB; Sigma T6199, 1:2000), histone H3 (H3; Abcam 
ab1791, 1:5000), and nucleophosmin (NPM; Abcam ab37659, 1:1500) used 
horseradish peroxidase-conjugated secondary antibodies (Jackson Immuno Research 
Laboratories) and Western Lightning Plus-ECL (Perkin Elmer) using a ChemiDoc 
Imaging System. 
 
Immunofluorescence—Cells were grown on glass coverslips coated with 0.8% gelatin, 
fixed with 4% paraformaldehyde, permeabilized with NP40, and blocked with 200µg/mL 
ChromPure IgG (Jackson Immuno Research Laboratories) corresponding to secondary 
antibody species. Detection for NPM used α-NPM (Life Technologies 325200; 1:1000) 
with secondary Alexa Fluor 350 donkey anti-mouse IgG (Life Technologies A10035; 
40µg/mL). GFP transfected cells were grown on glass coverslips and fixed with 4% 
paraformaldehyde. Coverslips were mounted on microscope slides using SlowFade 
Antifade reagent (Life Technologies S2828). Slides were imaged on a Zeiss Axioskop 2 
mot plus microscope with a Zeiss AxioCam MRm camera with a x40 oil immersion 
objective at room temperature. Images were acquired using AxioVision Rel. 4.8 
software. Images were processed identically using the ImageJ software package 
(rsb.info.nih.gov). 
 
Statistics—Biochemical results are presented as mean + SEM for a minimum of 3 
independent experiments. Statistical significance was assessed by two-tailed unpaired 
t-test. P-value < 0.05 was considered significant. 
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